America’s Medical Civil War
The Affordable Care Act has redefined federalism in America by creating new mechanisms for the state and nation to provide...
When Data Becomes Due Process
Prosecutors often use patient data to investigate physicians. But patient data is biased, lacking the robustness required of evidence. And...
COVID Vaccines for Kids
COVID-19 vaccines have been approved for children ages 5-11, a decision most had already anticipated. But lost in the predictability...
America United International, Protecting Individuals Against Judicial Misconduct
Dr. Zena Crenshaw-Logal has taken what she learned as an advocate for judicial reform to launch America United International.
The Media Has Failed Healthcare
The rise in healthcare journalism has led to a rise in biased healthcare articles – with many articles written through...
First Principles of Healthcare
First principles thinking attempts to break down complex concepts into its fundamental parts. When we apply this thinking to healthcare,...
Moderna, a Modern Medical Company
Moderna's decision to restrict the licensing rights of its vaccine came as a surprise to many. But for those who...
The DEA’s Long Game
The DEA recently issued a public health alert, warning of counterfeit pills. A seemingly odd alert given the DEA's restrictions...
Vaccine or Treatment
The public perceives the pandemic through binary thinking, as though playing a zero sum game. But healthcare is not binary....
Abortion’s Precedent
America's regulation of abortion sets a concerning precedent for all of healthcare. As we expand healthcare coverage, we must caution against...
What ‘Doing Research’ Really Means
A phrase we hear frequently of late, often among prominent personalities with little to no formal scientific training. We decode...
Mixing and Matching Vaccines
The CDC might reverse course again, this time on mixing vaccine formularies. We review the science and politics underlying the...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more